Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Can-Fite BioPharma Ltd. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 15 | 12 | −3 |
| Shares | 443.1K | 459.3K | +16.2K (+3.6%) |
| Value | $1.09M | $1.05M | −$47.3K (−4.3%) |
New holders (2)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| StoneX Group Inc. | 40,000 | $91.0K | 0.01% |
| UBS Group AG | 7,709 | $18.0K | 0.00% |
Sold out (5)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Virtu Financial LLC | 46,294 | $114.0K |
| XTX Topco Ltd | 11,205 | $28.0K |
| Jane Street Group, LLC | 10,665 | $26.0K |
| Bank of Montreal | 66 | $0 |
| Wealthcare Advisory Partners LLC | 200 | $0 |